Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OCTREOTIDE Cause Malignant neoplasm progression? 2,306 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 2,306 reports of Malignant neoplasm progression have been filed in association with OCTREOTIDE (Octreotide Acetate). This represents 9.7% of all adverse event reports for OCTREOTIDE.

2,306
Reports of Malignant neoplasm progression with OCTREOTIDE
9.7%
of all OCTREOTIDE reports
610
Deaths
1,109
Hospitalizations

How Dangerous Is Malignant neoplasm progression From OCTREOTIDE?

Of the 2,306 reports, 610 (26.5%) resulted in death, 1,109 (48.1%) required hospitalization, and 95 (4.1%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OCTREOTIDE. However, 2,306 reports have been filed with the FAERS database.

What Other Side Effects Does OCTREOTIDE Cause?

Death (3,801) Diarrhoea (3,621) Fatigue (2,933) Blood pressure increased (2,799) Needle issue (2,740) Malaise (2,737) Pain (2,366) Blood pressure systolic increased (2,340) Nausea (2,294) Injection site pain (2,123)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which OCTREOTIDE Alternatives Have Lower Malignant neoplasm progression Risk?

OCTREOTIDE vs OCTREOTIDE\OCTREOTIDE OCTREOTIDE vs ODEVIXIBAT OCTREOTIDE vs OFATUMUMAB OCTREOTIDE vs OFLOXACIN OCTREOTIDE vs OLANZAPINE

Related Pages

OCTREOTIDE Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression OCTREOTIDE Demographics